Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas

American Journal of Surgical Pathology

Volumn 35, Issue 7, 2011, Pages 1014-1020

  Chaux, Alcides ^a   Albadine, Roula ^a   Toubaji, Antoun ^a   Hicks, Jessica ^a   Meeker, Alan ^a,b   Platz, Elizabeth A ^b   De Marzo, Angelo M ^a,b   Netto, George J ^a,b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Edel; ERG expression; Esplit; fluorescence in situ hybridization; prostate adenocarcinoma; TMPRSS2 ERG fusion

Indexed keywords

BIOLOGICAL MARKER; DNA; ERG PROTEIN, HUMAN; ONCOPROTEIN; TMPRSS2 ERG FUSION PROTEIN, HUMAN; TMPRSS2-ERG FUSION PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; CELL NUCLEUS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENE FUSION; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; TISSUE MICROARRAY;

ADENOCARCINOMA; BIOLOGICAL MARKERS; CELL NUCLEUS; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FUSION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; ONCOGENE PROTEINS, FUSION; PROSTATECTOMY; PROSTATIC NEOPLASMS; ROC CURVE; TISSUE ARRAY ANALYSIS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 79959660044     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31821e8761     Document Type: Article

References (46)

1. Albadine R, Latour M, Toubaji A, et al. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma. Mod Pathol. 2009;22:1415-1422.
2. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene. 2008;27:253-263.
3. Barry M, Perner S, Demichelis F, et al. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology. 2007;70:630-633. (Pubitemid 350030260)
4. Carver BS, Tran J, Gopalan A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009;41:619-624.
5. Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev Urol. 2009;6:429-439.
6. Clark J, Merson S, Jhavar S, et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene. 2007;26: 2667-2673. (Pubitemid 46632014)
7. Collinson P. Of bombers, radiologists, and cardiologists: time to ROC. Heart. 1998;80:215-217.
8. Demichelis F, Fall K, Perner S, et al. TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26:4596-4599. (Pubitemid 47037039)
9. Esgueva R, Perner S, J LaFargue C, et al. Prevalence of TMPRSS2- ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort. Mod Pathol. 2010;23:539-546.
10. Fine SW, Gopalan A, Leversha MA, et al. TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol. 2010;23:1325-1333.
11. FitzGerald LM, Agalliu I, Johnson K, et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer. 2008;8:230.
12. Furusato B, Gao CL, Ravindranath L, et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol. 2008;21:67-75. (Pubitemid 351172158)
13. Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis. 2010;13:228-237.
14. Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res. 2009;69:1400-1406.
15. Han B, Mehra R, Dhanasekaran SM, et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res. 2008;68:7629-7637.
16. Han B, Mehra R, Lonigro RJ, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol. 2009;22:1083-1093.
17. Hermans KG, van Marion R, van Dekken H, et al. TMPRSS2: ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res. 2006; 66:10658-10663. (Pubitemid 44876959)
18. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
19. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-847. (Pubitemid 28331029)
20. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008;8:497-511.
21. Lapointe J, Li C, Giacomini CP, et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res. 2007;67:8504-8510. (Pubitemid 47437424)
22. Lotan TL, Toubaji A, Albadine R, et al. TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas. Mod Pathol. 2009;22:359-365.
23. Mackinnon AC, Yan BC, Joseph LJ, et al. Molecular biology underlying the clinical heterogeneity of prostate cancer: an update. Arch Pathol Lab Med. 2009;133:1033-1040.
24. Mehra R, Han B, Tomlins SA, et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res. 2007;67:7991-7995. (Pubitemid 47395131)
25. Mehra R, Tomlins SA, Yu J, et al. Characterization of TMPRSS2- ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res. 2008;68:3584-3590.
26. Mosquera JM, Perner S, Genega EM, et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res. 2008;14:3380-3385.
27. Mosquera JM,Mehra R, Regan MM, et al. Prevalence of TMPRSS2- ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res. 2009;15:4706-4711.
28. Nam RK, Sugar L, Yang W, et al. Expression of the TMPRSS2: ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer. 2007;97:1690-1695. (Pubitemid 350249347)
29. Narod SA, Seth A, Nam R. Fusion in the ETS gene family and prostate cancer. Br J Cancer. 2008;99:847-851.
30. Park K, Tomlins SA, Mudaliar KM, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010;12: 590-598.
31. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2: ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006;66:8337-8341. (Pubitemid 44449140)
32. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol. 2007;31:882-888. (Pubitemid 47165141)
33. Petrovics G, Liu A, Shaheduzzaman S, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005;24:3847-3852. (Pubitemid 40826884)
34. Pflueger D, Rickman DS, Sboner A, et al. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia. 2009;11:804-811.
35. Pflueger D, Terry S, Sboner A, et al. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res. 2011;21:56-67.
36. Saramaki OR, Harjula AE, Martikainen PM, et al. TMPRSS2: ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res. 2008;14:3395-3400.
37. Scheble VJ, Braun M, Beroukhim R, et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol. 2010;23:1061-1067.
38. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.
39. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644-648. (Pubitemid 41528150)
40. Tomlins SA, Bjartell A, Chinnaiyan AM, et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol. 2009;56:275-286.
41. Toubaji A, Albadine R, Meeker A, et al. Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. Mod Pathol. 2011 (In press).
42. Tu JJ, Rohan S, Kao J, et al. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol. 2007;20:921-928. (Pubitemid 47267823)
43. Wang J, Cai Y, Ren C, et al. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res. 2006;66:8347-8351. (Pubitemid 44449142)
44. Winnes M, Lissbrant E, Damber JE, et al. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep. 2007;17: 1033-1036.
45. Yoshimoto M, Joshua AM, Chilton-Macneill S, et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia. 2006;8:465-469. (Pubitemid 44035330)
46. Yoshimoto M, Joshua AM, Cunha IW, et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol. 2008;21: 1451-1460.